←AMGN · $407.78

Amgen

AMGN · Pre-market

$407.78

+0.43% today·exchange $407.78

exchange $407.78

Sep 15$374.89 – $411.49Sep 24

1D 1W 1M 1Y

News · Amgen

Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease
Simply Wall St. · 7h ago
Amgen price target raised by Jefferies to $410 after positive Sjögren's data
Proactive · 14h ago
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Zacks · 17h ago
Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets
TIKR · 19h ago
Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results
TIKR · 19h ago
Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating
MT Newswires · 20h ago

Headlines from Yahoo Finance. Not investment advice.

About

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Industry: Healthcare
CEO: Robert A. Bradway